Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Informed Consent for Whole Genome Sequencing: Civic Ideals and Social Norms Referenced by Early Participants
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Glycemic Effects of Honey
Glycemic Effects of Honey
Status: Enrolling
Updated:  12/31/1969
Grand Forks Human Nutrition Research Center
mi
from
Grand Forks, ND
Glycemic Effects of Honey
Glycemic Effects of Honey
Status: Enrolling
Updated: 12/31/1969
Grand Forks Human Nutrition Research Center
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
ClinTriCo
mi
from
Phoenix, AZ
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
ClinTriCo
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles UCLA Tiverton
mi
from
Los Angeles, CA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles UCLA Tiverton
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Harbor-UCLA Medical Center LA Biomed
mi
from
Torrance, CA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Harbor-UCLA Medical Center LA Biomed
mi
from
Torrance, CA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine/Winship Cancer Institute G2304 - C2301
mi
from
Atlanta, GA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine/Winship Cancer Institute G2304 - C2301
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Pituitary Center, Division of Endocrinology SC
mi
from
Baltimore, MD
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Pituitary Center, Division of Endocrinology SC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of Michigan Comprehensive Cancer Center SC-2
mi
from
Ann Arbor, MI
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of Michigan Comprehensive Cancer Center SC-2
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine Mt. Sinai Medical Center
mi
from
New York, NY
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine Mt. Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Sciences University DeptofOregonHealth&Sciences(2)
mi
from
Portland, OR
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Sciences University DeptofOregonHealth&Sciences(2)
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania - Clinical Studies Unit Unniv SC
mi
from
Philadelphia, PA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania - Clinical Studies Unit Unniv SC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center CSOM230G2304
mi
from
Nashville, TN
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center CSOM230G2304
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center Swedish
mi
from
Seattle, WA
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center Swedish
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin MCW 2
mi
from
Milwaukee, WI
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin MCW 2
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Buenos Aires,
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated:  12/31/1969
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated: 12/31/1969
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated:  12/31/1969
New Mexico VA Health Care System, Albuquerque, NM
mi
from
Albuquerque, NM
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
CYP19A1 Gene and Pharmacogenetics of Response
Status: Enrolling
Updated: 12/31/1969
New Mexico VA Health Care System, Albuquerque, NM
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Effect of Dietary Glycemic Index on Beta-cell Function
Effect of Dietary Glycemic Index on Beta-cell Function
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Effect of Dietary Glycemic Index on Beta-cell Function
Effect of Dietary Glycemic Index on Beta-cell Function
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Altered Resting Energy Expenditure as a Cause of Obesity in Pseudohypoparathyroidism 1a: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Mifepristone for Metabolic Syndrome
Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Mifepristone for Metabolic Syndrome
Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS007)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess
Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (CBS003)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Center for Research in Reproduction
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Mood and Insulin Resistance in Adolescents At-Risk for Diabetes
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Caveolin-1 and Vascular Dysfunction
Caveolin-1 and Vascular Dysfunction
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Caveolin-1 and Vascular Dysfunction
Caveolin-1 and Vascular Dysfunction
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated:  12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Effect of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenic Adolescent Girls (JCM021)
Status: Enrolling
Updated: 12/31/1969
Center for Research in Reproduction, University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Status: Enrolling
Updated:  12/31/1969
Diabetes Division, UTHSCSA
mi
from
San Antonio, TX
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Status: Enrolling
Updated: 12/31/1969
Diabetes Division, UTHSCSA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Pharmacokinetic and Pharmacodynamic Studies of Liothyronine. A Study on the Metabolic Effects of Thyroid Hormone
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)
Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)
Status: Enrolling
Updated:  12/31/1969
Clinical Nutrition Research Center
mi
from
Chicago, IL
Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)
Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)
Status: Enrolling
Updated: 12/31/1969
Clinical Nutrition Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Prospective Evaluation of the Effect of Corticotropin-Releasing Hormone Stimulation on 18F-Fludeoxyglucose High-Resolution Positron-Emission Tomography in Cushing's Disease
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Status: Enrolling
Updated:  12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Status: Enrolling
Updated: 12/31/1969
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance
Translational Diabetes Prevention in GDM
Status: Enrolling
Updated:  12/31/1969
Division of Research Northern California
mi
from
Oakland, CA
Lifestyle Intervention Program for Women With Gestational Diabetes or Gestational Impaired Glucose Tolerance
Translational Diabetes Prevention in GDM
Status: Enrolling
Updated: 12/31/1969
Division of Research Northern California
mi
from
Oakland, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Southern California Permanente Medical Group
mi
from
Downey, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Miller Children's Hospital
mi
from
Long Beach, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Central California
mi
from
Madera, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
mi
from
Denver, CO
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials